Edwards Lifesciences Corporation (EW)
| Market Cap | 54.87B +13.3% |
| Revenue (ttm) | 6.51B +14.6% |
| Net Income | 1.00B -75.8% |
| EPS | 1.72 -75.5% |
| Shares Out | 576.40M |
| PE Ratio | 55.37 |
| Forward PE | 30.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 6,524,904 |
| Open | 93.67 |
| Previous Close | 93.26 |
| Day's Range | 93.27 - 96.09 |
| 52-Week Range | 74.66 - 96.29 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | 101.87 (+7.02%) |
| Earnings Date | Nov 4, 2026 |
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor... [Read more]
Financial Performance
In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for EW stock is "Buy." The 12-month stock price target is $101.87, which is an increase of 7.02% from the latest price.
News
Edwards Lifesciences Transcript: Investor update
CLASP IITR met its six-month endpoint, with PASCAL benefits driven mainly by health status. PROGRESS found lower two-year death or HF-event risk with TAVR in at-risk moderate AS, alongside strong safety and fewer HF hospitalizations.
Edwards Lifesciences announces results from CLASP II TR trial of PASCAL system
Edwards Lifesciences (EW) announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the six-month primary endpoint of the CLASP II TR trial. ...
CLASP II TR Trial Demonstrates Superior Clinical, Quality-of-Life Benefits With Edwards PASCAL System
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the PASCAL system for tricuspid repair demonstrated superiority compared to medical therapy alone for the s...
Edwards announced results from PROGRESS trial
Edwards Lifesciences (EW) announced results from the PROGRESS Trial in the management of moderate aortic stenosis. The trial demonstrated that transcatheter aortic valve replacement, or TAVR, was supe...
Progress Trial Demonstrates Edwards TAVR Is Superior to Clinical Surveillance for Moderate AS Patients With At-Risk Features
SAN DIEGO--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the PROGRESS Trial, marking a turning point in the management of moderate aortic stenosis (AS). The trial demon...
Edwards Lifesciences added to ‘Core Ideas’ list at Evercore, Illumina removed
Evercore ISI raised the firm’s price target on Edwards Lifesciences (EW) to $102 from $100 and keeps an Outperform rating on the shares, which were also added to the firm’s…
Edwards Lifesciences announces U.S. FDA approval of PASCAL Precision
Edwards Lifesciences (EW) announced that the U.S. Food and Drug Administration, FDA, has approved its PASCAL Precision system for tricuspid valve repair. The system is indicated for improving quality ...
FDA Approval of Edwards Lifesciences' PASCAL Precision System Opens New Treatment Pathway for Patients With Tricuspid Valve Disease
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved its PASCAL Precision system for tricuspid val...
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will hos...
Edwards Lifesciences initiated with an Overweight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Edwards Lifesciences (EW) with an Overweight rating and $110 price target The firm rolled out coverage of the medical suppliers and devices ...
Citi opens ‘upside 90-day catalyst watch’ on Edwards Lifesciences
Citi opened an “upside 90-day catalyst watch” on Edwards Lifesciences (EW) while keeping a Buy rating on the shares with a $110 price target Citi expects the company’s two trial…
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov...
Edwards Lifesciences receives FDA approval for AUTUS valve
Edwards Lifesciences (EW) “announced that the U.S. Food and Drug Administration has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients wi...
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary val...
Edwards Lifesciences Transcript: Deutsche Bank 2026 Healthcare Summit
The summit highlighted a clear focus on structural heart disease, with regulatory changes expanding TAVR access and multi-year growth opportunities. Innovation in product lines and clinical trials, especially in TMTT, supports ambitious revenue targets, while disciplined capital allocation and global expansion remain priorities.
Edwards Lifesciences comments on TAVR national coverage decision
Edwards Lifesciences (EW) issued a statement in response to the national coverage determination, or NCD, for transcatheter aortic valve replacement, or TAVR, released by the Centers for Medicare & Med...
Edwards Lifesciences Comments on TAVR National Coverage Decision
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacemen...
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive off...
Edwards Lifesciences management to meet with Piper Sandler
Meeting to be held on September 2 hosted by Piper Sandler.
Edwards Lifesciences upgraded to Buy from Neutral at UBS
UBS upgraded Edwards Lifesciences (EW) to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwards Lifesciences is entering a new…
Edwards Lifesciences price target raised to $105 from $100 at JPMorgan
JPMorgan raised the firm’s price target on Edwards Lifesciences (EW) to $105 from $100 and keeps an Overweight rating on the shares.
Leerink upgrades Edwards Lifesciences to Outperform, raises target to $101
As previously reported, Leerink upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a price target of $101, up from $87. The firm says it has seen “enough to…
Edwards Lifesciences price target raised to $101 from $100 at Piper Sandler
Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $101 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported strong…